Gastrointestinal side effects were cited by 7% of participants as their reason for coming off the drug
For those focused specifically on abdominal fat, the peptides for belly fat resource and the best peptide for visceral fat loss guide provide additional context on how GLP-1 and GIP agonists target different fat depots
Harvard Health Publishing
[DOI] [PMC free article] [PubMed] [Google Scholar] 103.Devries S., Dalen J.E., Eisenberg D.M., Maizes V., Ornish D., Prasad A., Sierpina V., Weil A.T., Willett W
Promising effects beyond weight loss Researchers are currently studying the effect of GLP-1s on a wide range of conditions beyond diabetes, obesity, and heart disease, including renal, hepatic, neurological, and substance-use disorders
When a user contributes shortage information to the GLP-1 Supply Tracker, Ro gives them the option of automatically reporting that information to the FDA, with no additional steps required